Company News

Cooperation on Projects | Leto Laboratories and Hanson Pharmaceutical Entered into Cooperation in Developing a New Drug for Metabolic Diseases

In September 2021, the Hanson Pharmaceutical Group Co., Ltd. (HKEX: 3692) ("Hanson Pharmaceutical") and Leto Laboratories Co., Ltd. ("Leto Laboratories") signed a co-development agreement, in which the parties agreed to carry out a cooperation on metabolic disease projects to facilitate the development and production of a new drug molecule.

Published: September 13, 2021

Company News

ChosenMed and Leto Laboratories Entered into a Strategic Cooperation on Predictive and Prognostic Molecular Marker Research for Solid Tumor Immunotherapy

On 19 January 2021, ChosenMed Technology (Beijing) Co., Ltd. (“ChosenMed”) and Leto Laboratories Co., Ltd. (“Leto Laboratories”) signed a strategic cooperation agreement in Beijing, to research in tandem on predictive and prognostic molecular markers for immunotherapy in solid tumors and advance the registration of companion diagnostic devices.

Published: January 19, 2021

Company News

State-of-the-Art Technology Facilitates Protein Manufacturing

Today let me introduce a successful case related to this topic- how Leto Laboratories Co., Ltd. develops and manufactures ACE2, a recombinant protein, with BioAccord system of Waters. This system has been used for virus research, development and quality control of vaccines, diagnostic reagents and therapeutic medications in many world-renowned research institutions and firms.

Published: May 15 ，2020